Mesoblast Limited (NASDAQ:MESO) Shows Neutral Momentum But Valuation Stays Elevated Ahead

Mesoblast arrives with mixed technical signals and improving cash flexibility while WMDST’s valuation classifies the stock as over-valued; near-term price action likely to trade rangebound with episodic volatility tied to corporate updates.

Recent News

Dec 29, 2025 — Mesoblast drew $75 million from a new five-year credit facility provided by a major shareholder, repaid an existing senior secured loan, and retains the option to draw a further $50 million through June 30, 2026; the facility carries an 8.00% fixed interest rate and includes five‑year warrants exercisable at a premium to recent VWAP.

Dec 21, 2025 — Analyst one‑year price targets were revised higher, lifting the average one‑year target to $20.25 per share from earlier estimates and showing a narrower range of analyst expectations.

Feb 20, 2026 — Company announced a webcast to present operational highlights and financial results for the half year ended Dec. 31, 2025, scheduled for Feb. 26, 2026 (with archive availability on the investor page).

Technical Analysis

ADX registers 9.51, indicating no prevailing trend; directional movement shows DI+ at 30.47 with a peak-and-reversal pattern (bearish) while DI‑ sits at 33.59 with a peak-and-reversal pattern (bullish), implying a tug-of-war between buyers and sellers and a likely rangebound near-term price bias relative to WMDST’s over‑valued assessment.

MACD equals -0.30 with the signal at -0.28 and a peak-and-reversal MACD_trend; negative and declining MACD denotes bearish momentum and no bullish MACD/signal crossover to offset that downside pressure.

MRO stands at -1.96 (negative), which indicates price sits below the calculated target and suggests upward pressure toward the target; given the small magnitude, expect only modest mean-reversion potential against the broader valuation headwind.

RSI of 49.02 with a decreasing trajectory signals neutral-to-weak momentum, consistent with sideways consolidation rather than a decisive directional move.

Price relationships: last close $16.91 sits marginally above the 20‑day average ($16.89) and 12‑day EMA ($16.95, decreasing), below the 50‑day average ($17.99), and above the 200‑day average ($15.44). Bollinger band midrange places the stock near the band center between $16.19 (lower 1x) and $17.58 (upper 1x), supporting a limited‑range outlook with defined intraday support near $16.35 (super trend lower).

Ichimoku components place price beneath Senkou A ($19.29) and Senkou B ($17.80) while below the Kijun‑sen ($17.45) and marginally below the Tenkan‑sen ($16.96), reinforcing the neutral-to-bearish technical posture until price clears the cloud boundary.

Volatility and volume: 42‑day volatility of 4% and a 10‑day average volume of 171,371 versus a 200‑day average of 228,025 suggest current trading interest slightly below longer-term norms; 42‑day beta 2.18 and 52‑week beta 1.60 indicate elevated sensitivity to market moves, amplifying swing potential despite the currently weak trend strength.

 


Fundamental Analysis

Revenue growth registers 20.50% (revenue growth = 0.20504), while reported quarter‑over‑quarter and year‑over‑year revenue growth figures read 0.0% (each), requiring attention to reporting definitions; WMDST uses the 20.50% figure when aligning growth to valuation implications. QoQ revenue change shows 0.0% and YoY revenue change shows 0.0% as reported.

Cash flow dynamics: beginning period cash stood at $144,719,000 and ending cash at $129,975,000, a cash flow delta of $-14,744,000; capital expenditures $-133,000 and operating cash flow reported at $0. Free cash flow equals $-15,691,000 with reported free cash growth of 2.86% (freeCashGrowth = 0.02858), a positive reading that sits above the industry peer mean free cash growth of -54.89% and above the industry peer median and range, indicating comparatively stronger free cash growth versus peers on the provided basis.

Free cash growth quarter‑over‑quarter reads -126.30% (freeCashGrowthQoQ = -1.26297) and year‑over‑year -181.40% (freeCashGrowthYoY = -1.81401) as reported; those large negative percentages reflect short-term volatility in cash generation and warrant monitoring of upcoming reported cash flow items during the next report date (Apr. 28, 2026).

Valuation metrics: forward EPS $0.0425 produces a forward P/E of 403.51, markedly higher than the industry peer mean forward P/E of 56.00 and the industry peer median near -0.84; that divergence places valuation well above peers on a forward earnings basis and aligns with WMDST’s determination that the current valuation is over‑valued. WMDST values the stock as over‑valued given the extreme forward P/E relative to peer central tendency and the negative free cash flow in absolute terms.

Targets and range: analyst price target mean sits at $19.22 with a high of $33.74 and a low of $9.13; the current last close of $16.91 lies below the mean target but well below the upper tail, reinforcing WMDST’s caution on valuation and the necessity for fundamental inflection to support material upside.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-01-27
NEXT REPORT DATE: 2026-04-28
CASH FLOW  Begin Period Cash Flow 144.7 M
 Operating Cash Flow 0.00
 Capital Expenditures -133.00 K
 Change In Working Capital
 Dividends Paid
 Cash Flow Delta -14.74 M
 End Period Cash Flow 130.0 M
 
INCOME STATEMENT REVENUE
 Total Revenue
 Forward Revenue
COSTS
 Cost Of Revenue
 Depreciation
 Depreciation and Amortization
 Research and Development
 Total Operating Expenses
PROFITABILITY
 Gross Profit
 EBITDA
 EBIT
 Operating Income
 Interest Income
 Interest Expense
 Net Interest Income
 Income Before Tax
 Tax Provision
 Tax Rate
 Net Income
 Net Income From Continuing Operations
EARNINGS
 EPS Estimate
 EPS Actual
 EPS Difference
 EPS Surprise
 Forward EPS 0.04
 
BALANCE SHEET ASSETS
 Total Assets
 Intangible Assets
 Net Tangible Assets
 Total Current Assets
 Cash and Short-Term Investments
 Cash
 Net Receivables
 Inventory
 Long-Term Investments
LIABILITIES
 Accounts Payable
 Short-Term Debt
 Total Current Liabilities
 Net Debt
 Total Debt
 Total Liabilities
EQUITY
 Total Equity
 Retained Earnings
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share
 Shares Outstanding
 Revenue Per-Share
VALUATION
 Market Capitalization
 Enterprise Value
 Enterprise Multiple
Enterprise Multiple QoQ
Enterprise Multiple YoY
Enterprise Multiple IPRWA
 EV/R
CAPITAL STRUCTURE
 Asset To Equity
 Asset To Liability
 Debt To Capital
 Debt To Assets
Debt To Assets QoQ
Debt To Assets YoY
Debt To Assets IPRWA
 Debt To Equity
Debt To Equity QoQ
Debt To Equity YoY
Debt To Equity IPRWA
PRICE-BASED VALUATION
 Price To Book (P/B)
Price To Book QoQ
Price To Book YoY
Price To Book IPRWA
 Price To Earnings (P/E)
Price To Earnings QoQ
Price To Earnings YoY
Price To Earnings IPRWA
 PE/G Ratio
 Price To Sales (P/S)
Price To Sales QoQ
Price To Sales YoY
Price To Sales IPRWA
FORWARD MULTIPLES
Forward P/E 403.507
Forward PE/G
Forward P/S
EFFICIENCY OPERATIONAL
 Operating Leverage
ASSET & SALES
 Asset Turnover Ratio
Asset Turnover Ratio QoQ
Asset Turnover Ratio YoY
Asset Turnover Ratio IPRWA
 Receivables Turnover
Receivables Turnover Ratio QoQ
Receivables Turnover Ratio YoY
Receivables Turnover Ratio IPRWA
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO)
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio
 CapEx To Revenue
 CapEx To Depreciation
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital
 Net Invested Capital
 Invested Capital -33.00 M
 Net Tangible Assets
 Net Working Capital
LIQUIDITY
 Cash Ratio
 Current Ratio
Current Ratio QoQ
Current Ratio YoY
Current Ratio IPRWA
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA
 Cost Of Debt 0.0 %
 Interest Coverage Ratio
Interest Coverage Ratio QoQ
Interest Coverage Ratio YoY
Interest Coverage Ratio IPRWA
 Operating Cash Flow Ratio
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO)
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate
 Revenue Growth 20.504 %
Revenue Growth QoQ 0.0 %
Revenue Growth YoY 0.0 %
Revenue Growth IPRWA high: 71.991 %
MESO: 20.504 %
median: 3.233 %
mean: 2.756 %
low: -83.784 %
 Earnings Growth
Earnings Growth QoQ
Earnings Growth YoY
Earnings Growth IPRWA
MARGINS
 Gross Margin
Gross Margin QoQ
Gross Margin YoY
Gross Margin IPRWA
 EBIT Margin
EBIT Margin QoQ
EBIT Margin YoY
EBIT Margin IPRWA
 Return On Sales (ROS)
Return On Sales QoQ
Return On Sales YoY
Return On Sales IPRWA
CASH FLOW
 Free Cash Flow (FCF) -15.69 M
 Free Cash Flow Yield
Free Cash Flow Yield QoQ
Free Cash Flow Yield YoY
Free Cash Flow Yield IPRWA
 Free Cash Growth 2.858 %
Free Cash Growth QoQ -126.297 %
Free Cash Growth YoY -181.401 %
Free Cash Growth IPRWA high: 124.18 %
MESO: 2.858 %
mean: -54.893 %
median: -69.41 %
low: -77.378 %
 Free Cash To Net Income
 Cash Flow Margin
 Cash Flow To Earnings
VALUE & RETURNS
 Economic Value Added
 Return On Assets (ROA)
Return On Assets QoQ
Return On Assets YoY
Return On Assets IPRWA
 Return On Capital Employed (ROCE)
 Return On Equity (ROE)
Return On Equity QoQ
Return On Equity YoY
Return On Equity IPRWA
 DuPont ROE
 Return On Invested Capital (ROIC)
Return On Invested Capital QoQ
Return On Invested Capital YoY
Return On Invested Capital IPRWA

Six-Week Outlook

Expect rangebound trading with episodic volatility driven by corporate updates and liquidity events. Technicals show neutral momentum: absence of a clear ADX trend, MACD bearish momentum, an MRO suggesting modest mean reversion, and RSI near 50. Market sensitivity remains elevated (42‑day beta 2.18), so macro moves could produce outsized intraperiod swings. Fundamental backdrop combines positive revenue growth and improved free cash growth versus industry peer mean but persistent negative free cash flow and an extreme forward P/E that keeps valuation elevated. Monitor upcoming company disclosures and the archived half‑year webcast for operational detail; absent new positive fundamentals, the path toward WMDST’s over‑valued classification resolving remains dependent on material improvements in cash generation or earnings visibility.

About Mesoblast Limited

Mesoblast Limited (NASDAQ:MESO) develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland. Utilizing a proprietary technology platform centered on mesenchymal lineage cells, Mesoblast creates innovative treatments targeting systemic inflammatory conditions and chronic diseases. The company advances Remestemcel-L, currently in Phase III clinical trials, for addressing steroid refractory acute graft versus host disease, biologic refractory inflammatory bowel disease, Crohn’s disease, chronic heart failure, and chronic low back pain linked to degenerative disc disease. Additionally, Mesoblast develops MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. Strategic alliances with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal enhance their offerings, including MPC-150-IM and MPC-25-IC for chronic heart failure and acute myocardial infarction, and cell therapies for wound healing and neonatal hypoxic ischemic encephalopathy. Established in 2004, Mesoblast operates from its headquarters in Melbourne, Australia, driving forward the field of regenerative medicine with its cutting-edge therapeutic solutions.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.